Senti Biosciences Holdings (SNTI): New Enterprise Associates 15, L.P. disclosed a 9.7% stake in SNTI and may seek to influence the company 9.7%
New Enterprise Associates 15, L.P. disclosed a 9.7% stake in SNTI and may seek to influence the company.
- 9.7%
- Stake
- 8.78M
- Shares owned
- Stake as of
- Nov 16, 2026
- Filed
- Nov 18, 2026
What stands out in this filing
- Reported stake 9.7% (8,775,115 shares).
- A 13D is filed by an owner of more than 5% who may seek to influence the company.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
Context
Written by software from the filings listed below · Nov 19, 2026
- What was filed. New Enterprise Associates 15, L.P. filed a SCHEDULE 13D/A on Nov 18, 2026 reporting 8,775,115 shares, 9.7% of the class of Senti Biosciences Holdings (SNTI). (SEC Schedule 13D)
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeThe story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 23, 2026, Brenda Cooperstone, Ph.D., notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the "Company") of her decision to resign from the Board, effective immediately.”
- Oct 21, 2026Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and signed an important agreement (and 2 more items)“The information provided in the Introductory Note and Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Celadon Partners, LLC (“Celadon”) controls Parent, Celadon Partners SPV 24 Limited, the Company’s largest stockholder, CPIF II-7 Limited, which purchased $14.0 million in aggregate principal amount of Midco’s Senior Secured Convertible Notes, and the Investor.”
- Oct 26, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 27, 2026, Edward Mathers notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the "Company") of his decision to resign from the Board, effective immediately.”
- Nov 9, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
- Nov 13, 20265% stakeNantahala Capital Management, LLC reported a passive stake (13G) of 4.1%
What came next
How to read SEC Schedule 13D
A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.
Full guide: Schedule 13D vs Schedule 13G: what is the difference?
What else is on file for Senti Biosciences Holdings
For Senti Biosciences Holdings, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SNTI page.
How this filing works
Explore the data
Common questions
What does this filing report about Senti Biosciences Holdings (SNTI) stock?
New Enterprise Associates 15, L.P. disclosed a 9.7% stake in SNTI and may seek to influence the company. Of the company, Schedule 13D (may seek influence).
When did it happen, and when was it made public?
Stake as of: Nov 16, 2026. Filed: Nov 18, 2026.
What stands out in this filing?
Reported stake 9.7% (8,775,115 shares). A 13D is filed by an owner of more than 5% who may seek to influence the company.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Schedule 13D, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Senti Biosciences Holdings recently?
For Senti Biosciences Holdings, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the SNTI page.
Does this mean SNTI stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Senti Biosciences Holdings
- SEC Schedule 13DNov 18, 2026
- SEC Schedule 13GNov 13, 2026
- SEC Form 4Feb 7, 2025
- SEC Form 4Feb 7, 2025
- SEC Form 4Feb 7, 2025
- SEC Form 4Feb 7, 2025
Everything OQRO holds on this company is on its SNTI page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
